Considering the molecular and cellular background of the disease, three strategies of disease modification in SMA are currently used: replacement of SMN1 gene, modulation of SMN2 gene splicing, and enhancement of the function of remaining muscles. Here, SMN1 is linked to proximal spinal muscular atrophy.